Fourth Insider in a Month at This Rare-Disease Play, But It's Stretched

ISB Research · Interesting · sent to Ultimate members September 2, 2026

Quoin is a late-stage drug shop chasing treatments for rare skin diseases like Netherton syndrome, and the COO just added $99,991 at $4.88. That's the fourth insider to step in over the past 30 days, and cluster buying like this is the kind of signal that usually gets my attention. The problem is timing. Price sits at $6.51 already, well above where these insiders bought, with RSI near 68 and money flow pinned at 98. The read is buy, but you'd be chasing here. Let it come back toward the $4.88 zone before you touch it.

Ultimate members received this analysis in real time.